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Abstract This systematic review and meta-analysis aimed to
evaluate the effects of cognitive behavioural therapy (CBT) on
depression, quality of life, hospitalisations and mortality in heart
failure patients. The search strategy was developed for Ovid
MEDLINE and modified accordingly to search the following
bibliographic databases: PubMed, EMBASE, PsycINFO,
CENTRAL andCINAHL.Databaseswere searched from incep-
tion to 6 March 2016 for randomised controlled trials (RCTs) or
observational studies that used CBT in heart failure patients with
depression or depressive symptoms. Six studies were identified:
5 RCTs and 1 observational study, comprising 320 participants
with predominantly NYHA classes II-III, who were mostly
male, with mean age ranging from 55 to 66 years. Compared
to usual care, CBTwas associated with a greater improvement in
depression scores both initially after CBT sessions (standardised
mean difference −0.34, 95% CI −0.60 to −0.08, p = 0.01) and at
3 months follow-up (standardised mean difference −0.32, 95%
CI −0.59 to −0.04, p = 0.03). Greater improvement in quality of
life scores was evident for the CBT group initially after CBT
sessions, butwith no difference at 3months. Hospital admissions
and mortality were similar, regardless of treatment group. CBT
may be more effective than usual care at improving depression
scores and quality of life for heart failure patients initially fol-
lowing CBT and for depression at 3 months. Larger and more
robust RCTs are needed to evaluate the long-term clinical effects
of CBT in heart failure patients.
Keywords Cognitive behavioural therapy . Depression .
Heart failure . Meta-analysis . Quality of life . Systematic
review
Introduction
Heart failure continues to impose a tremendous burden on
patients, carers and healthcare systems. In Europe, approxi-
mately 6.5 million people are currently living with the condi-
tion [1], with a prevalence of ≥10% among the 70 years and
older population [2]. Heart failure is the endpoint of all car-
diovascular diseases [3], and therefore, the improved survival
rates for other cardiovascular diseases are expected to further
increase the prevalence, in addition to the increase due to the
ageing population [2]. It is a significant cause of mortality,
with approximately 5% of all deaths attributable to heart fail-
ure in the UK [4], and only 25% of patients are expected to
survive beyond 5 years after their first hospital admission
[5]—a prognosis that is worse than most cancers [6]. The
morbidity associated with heart failure costs the UK
National Health Service (NHS) around 2% of its annual bud-
get, which is primarily through costs associated with
hospitalisation [7]. Two percent of all hospitalised bed-days
and 5% of all emergency hospital admissions are a result of
heart failure [4, 8].
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Depression is characterised by symptoms that affect a pa-
tient’s cognitive, emotional and behavioural processes [9]. The
association between depression and heart failure has been dem-
onstrated in numerous studies; however, the specific rate of
prevalence varies, ranging from 9% [10] to as much as 60%
[11], with one meta-analysis reporting a pooled estimate of
22% [12]. The existence of depression has negative implica-
tions for heart failure patients, particularly through reduced
survival and an increased risk of secondary events [12–15].
The precise mechanism by which depression causes poorer
outcomes in heart failure patients is unclear, but is thought to
be a combination of behavioural influences and their interac-
tion with physiological responses [16–18]. In addition, the be-
havioural influences of depression can reduce the likelihood of
both treatment adherence [19] and modifying lifestyle behav-
iours [16], which may further contribute to adverse outcomes.
Cognitive behavioural therapy (CBT) refers to a group of psy-
chological interventions that aim to understand a patient’s normal
cognitive and behavioural processes, and modify these to elimi-
nate negative cognitions and behaviours [20, 21]. CBT is a well-
established intervention in depression, and is currently recom-
mended in guidelines [22], but its effectiveness for depression in
heart failure patients remains unclear [23]. Two previous system-
atic reviews only identified one study that had examined psycho-
logical interventions for depression in heart failure patients [3, 24].
For a condition with an already poor prognosis and reduced qual-
ity of life, the potential for further deterioration with concomitant
depression needs to be addressed. This systematic review evalu-
ated the effectiveness of CBT for heart failure patients with de-
pression by assessing changes in depression scores, impact on
quality of life (QoL) and rates of hospitalisation and mortality.
Methods
This systematic review and meta-analysis was prospectively
registered with the PROSPERO database of systematic re-
views (CRD42016036146) [25] and reported in accordance
with the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) guidelines [26].
Study selection
The search strategy was developed by the research team and
checked by an information specialist prior to implementation
(see Supplementarymaterial 1). The strategy included specific
terms relevant to the study objectives: CBT, heart failure and
depression. It was primarily developed for Ovid MEDLINE,
before adaptation for use in other bibliographic databases. The
following bibliographic databases were searched from incep-
tion to 6 March 2016: PubMed/MEDLINE, EMBASE,
PsycINFO, Cochrane Central Register of Controlled Trials
(CENTRAL) and CINAHL. Grey literature was found
through contacting lead authors on heart failure for unpub-
lished studies and through manual searches of reference lists
of included papers. Two reviewers independently screened the
titles, abstracts and full texts of studies, as appropriate, for
potentially relevant studies. Disagreements were resolved
through discussion or adjudication by a third person.
Inclusion and exclusion criteria
Both randomised controlled trials (RCTs) and observational
studies were eligible for inclusion. Studies were only included
if they met the following criteria: participants were ≥18 years,
with a clinical diagnosis of heart failure as defined by each
study (usually relating to a combination of clinical symptoms
and identification of either systolic or diastolic dysfunction)
and with depression or depressive symptoms (above or equal
to a predefined cut-off on validated depression questionnaires).
The intervention was CBT, as described by authors, entailing
both cognitive and behavioural components; studies compris-
ing solely of cognitive or behavioural therapies were excluded,
as were CBT interventions as part of a more comprehensive
package (e.g. with exercise). Comparators included usual care,
exercise, medication or no treatment. There were no language
restrictions imposed, but accessibility of full-text publication
was a requirement. Two reviewers independently determined
eligibility for inclusion/exclusion, with disagreements
discussed and referred to a third reviewer if required.
Outcomes
The following outcomes were of interest: change in depression
(assessed through changes to depression scores on validated
questionnaires), quality of life (assessed by a validated quality
of life questionnaire) and clinical outcomes of hospitalisation
and mortality (both all-cause mortality and cardiovascular mor-
tality). However, there was insufficient information on cause of
death to examine the impact of CBTon cardiovascular mortality.
Data extraction and risk of bias assessment
Two reviewers used a standardised data extraction form to in-
dependently extract the following information: study popula-
tion (baseline characteristics, sample size, definition of heart
failure and assessment of depression/depressive symptoms),
CBT intervention (description of CBT, duration and frequency),
comparator (type of comparator, duration and frequency) and
the outcomes (method of assessment, depression scores, quality
of life scores, number of hospitalisations and deaths). Included
studies were assessed for methodological quality using risk of
bias assessment tools. For RCTs, the Cochrane Risk of Bias
tool [27] was used, which considers selection bias
(randomisation and allocation concealment), performance bias
(blinding of participants and comparators), detection bias
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(blinding of assessed outcomes), attrition bias (incomplete out-
come data) and reporting bias. For the assessment of observa-
tional studies, the Risk of Bias Assessment tool for Non-
randomised Studies (RoBANS) [28] was employed.
Statistical analysis
The outcome data from included studies were reported as either
dichotomous or continuous variables. For dichotomous data, the
risk ratio and 95% confidence intervals were reported. For con-
tinuous variables, the mean differences (MD) between CBT and
comparator groups were reported, with standardisedmean differ-
ences (SMD) and 95% confidence intervals calculated. In studies
where the mean difference was not reported, it was calculated for
relevant time-points by using individual patient data obtained
from the authors of individual studies. A meta-analysis of quan-
titative data was performed using fixed-effects modelling, under
the assumption that there would be a similar effect from trials
with similar patient populations and outcomes [29]. As a sensi-
tivity analysis, we performed random effects modelling using the
method of DerSimonian and Laird [30]. For outcomes measured
by different questionnaires, subgroup analyses were performed
separately for all questionnaires and for questionnaires which
were common across included studies. All effect estimates were
accompanied by 95% confidence intervals and assessed for het-
erogeneity (using the I2 statistic). All statistical tests were two-
tailed, and p values of <0.05 were considered statistically signif-
icant. Meta-analysis was performed using Review Manager
(RevMan) version 5.3 (The Nordic Cochrane Centre,
Copenhagen, 2014).
Results
Identification and selection of studies
The searches revealed a total of 454 papers, reduced to 298
papers after removing duplicates (Fig. 1). After independent
screening of titles and abstracts, 287 papers were determined
ineligible, with 11 papers retrieved for further evaluation. An
additional three papers were obtained through contacting lead
authors and grey literature search, resulting in 14 papers for
further evaluation. Of these, four papers were excluded due to
inappropriate populations [31–34]; three papers were exclud-
ed as information on heart failure patients could not be isolat-
ed from the study population, despite contacting authors
[35–37]; two papers were excluded due to inappropriate inter-
ventions [38, 39] (see Supplementary material 2). Of the re-
maining five papers [40–44], one was an abstract that com-
bined data for two separate RCTs [44]; therefore, the lead
author was contacted, and provided the individual patient data
and corresponding protocols for the two studies (referred to as
Dekker, 2010 Personal Communication and Dekker, 2011
Personal Communication from here on). Therefore, six stud-
ies were included in this systematic review.
Description of included studies
The six studies comprised 320 participants with predom-
inantly New York Heart Association (NYHA) classes II-
III, who were mostly male (ranging from 43 to 70%
across studies), with mean ages ranging from 55 to
66 years (Table 1). Five were RCTs [40–42 Dekker
454 papers idenfied through
PubMed/Medline, EMABSE,
PsycINFO, CENTRAL and CINAHL
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2010, Dekker 2011], and one study was observational
[43]. Four of the RCTs had one intervention group whilst
one [42] had three intervention groups (one was a combi-
nation of CBT with exercise and was excluded from these
analyses). In all the RCTs, the CBT intervention consisted
of individual, face-to-face sessions that were delivered by
an experienced nurse or therapist. These sessions varied in
frequency and duration: three studies had single sessions
each lasting 30 min [40, Dekker 2010, Dekker 2011]; one
study had weekly sessions lasting 60 min for 12 weeks
[42]; and one study initially had 60-min weekly sessions,
before tapering to bi-weekly and then bi-monthly ses-
sions, for a total of 6 months [41]. The CBT sessions
generally involved building rapport with patients, under-
standing patient thoughts and behaviours about heart fail-
ure, educating patients about depression and setting and
reviewing assignments. For all RCTs, the face-to-face
CBT sessions were followed up by ‘booster’ CBT tele-
phone sessions. The comparator in the RCTs was usual
care only, with one study having a second, exercise only
comparator group. The observational study was a proof-
of-concept study, which consisted of an Internet-based
programme that delivered CBT modules over a 9-week
period, with contact with healthcare professionals only
through written feedback on assignments. Attrition rates
were low across studies, except for two studies [Dekker
2010; Dekker 2011], where there were significant losses
to follow-up beyond the 1 week time-point (Table 1).
Risk of bias
For the five RCTs, the process of randomisation was de-
scribed in adequate detail for three studies [40 Dekker
2010, Dekker 2011], but for two studies, the precise meth-
od of random sequence generation was not clear [41, 42].
Allocation concealment was only explained thoroughly in
Freedland et al. [41]. Given the nature of the CBT inter-
vention, blinding of participants was not possible; only
two studies sufficiently explained the blinding of outcome
assessors [40, 41] (Fig. 2). Incomplete outcome data was
addressed in three RCTs with appropriate reasons provid-
ed for attrition and similar rates between groups [40–42].
Selective reporting was difficult to ascertain due to a lack
of published protocols. The RCTs were free from other
sources of bias, except for one study [40] with potential
social desirability bias due to the follow-up questionnaires
being administered by the same nurse that delivered the
intervention. For the observational study, the nature of the
CBT intervention could have resulted in sampling bias, as
patients required access to the Internet and basic computer
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skills. Further, the level of exposure participants had to
the intervention is unclear, as no healthcare professionals
were present during the intervention itself. Some potential
confounding variables were not included (i.e. severity of
heart failure), but there were no signs of attrition bias or
selective outcome reporting. Small study bias could not be
assessed by testing for funnel plot asymmetry as there
were <10 studies [29] in this meta-analysis.
Outcomes
For depression and quality of life, the effects of CBT were
evaluated at two time-points: the first time-point was after
the main CBT phase and again 3 months later, due to the
differing lengths of CBT and follow-up points in each trial
(Table 1; Fig. 3).
Depression
The change in depressive symptoms was assessed by depres-
sion scores on validated questionnaires. All the RCTs used
mean Beck’s Depression Inventory (BDI-II) scores, except
one [41], which used the Hamilton Rating Scale for
Depression (HAM-D); some also used an additional depres-
sion questionnaire (HAM-D or Patient Health Questionnaire
(PHQ-9) [41, 42 Dekker 2010, Dekker 2011]. The observa-
tional study [43] used the PHQ-9 and Montgomery-Åsberg
Depression Rating Scale (MADRS) and was not included in
the meta-analysis. This study [43] demonstrated a decrease in
median depression scores from baseline (PHQ-9 11, MADRS
25.5) to 9 weeks (PHQ-9 8.5, MADRS 16.5). Similarly, all
RCTs demonstrated improvement in the mean depression
scores in both intervention and comparator groups when com-
pared to baseline depression scores at any of the follow-up
points [40–42, Dekker 2010, Dekker 2011] (Table 2).
Immediately after completion of the main CBT phase,
there was a greater improvement in depression for the CBT
group compared to the usual care group for BDI-II scores
(SMD −0.35, 95% CI −0.63 to −0.07, p = 0.01, I2 = 0%)
and across all depression scales (SMD −0.34, 95% CI
−0.60 to −0.08, p = 0.01, I2 = 0%) (Fig. 3a). Three months
after the main CBT phase, there was still a greater im-
provement in the CBT group than in the usual care group
for BDI-II scores (SMD −0.30, 95% CI −0.61 to −0.00,
Depression inially aer main CBT phase (all depression scales)
Study Standardised
Mean Difference
95% Confidence
Interval
Gary 2010 -0.25 -0.95, 0.44
Dekker 2010 -0.02 -1.04, 0.99
Dekker 2011 -0.12 -1.05, 0.81
Dekker 2012 -0.36 -1.00, 0.28
Freedland 2015 -0.42 -0.77, -0.08
Overall effect (p=0.01)
Heterogeneity (I2=0%, p=0.93)
-0.34 -0.60, -0.08
Depression 3 months aer main CBT phase (all depression scales)
Study Standardised
Mean Difference
95% Confidence
Interval
Gary 2010 -0.38 -1.11, 0.34
Dekker 2010 0.37 -1.00, 1.73
Dekker 2011 -0.14 -1.37, 1.09
Dekker 2012 -0.19 -0.87, 0.49
Freedland 2015 -0.40 -0.76, -0.03
Overall effect (p=0.03)
Heterogeneity (I2=0%, p=0.85)
-0.32 -0.59, -0.04
a
b
Fig. 3 Forest plots summarising the effectiveness of CBT versus usual care on depression. Meta-analysis of all depression scales (BDI-II and HAM-D)
at the first time-point initially after the main CBT phase (a) and at 3 months (b). CBT cognitive behavioural therapy
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p = 0.05, I2 = 0%) and across all depression scales (SMD
−0.32, 95% CI −0.59 to −0.04, p = 0.03, I2 = 0%) (Fig. 3b).
This demonstrates a moderate size effect initially after the
main CBT phase which was maintained 3 months later, and
there was no evidence of heterogeneity (I2 = 0%). For the
one study [42] that compared CBT to exercise, there was
no difference in depression at 3 months for HAM-D scores
(MD −0.34, 95% CI −4.93 to 4.24).
Quality of life
Quality of life was only assessed in the RCTs. Four stud-
ies used the Minnesota Living with Heart Failure
Questionnaire (MLHFQ) [40, 42, Dekker 2010, Dekker
2011], whilst Freedland et al. [41] used both the Kansas
City Cardiomyopathy Questionnaire (KCCQ) and the
Short Form 12-item (SF-12). There were improvements
in quality of life scores for the CBT intervention groups
across all five RCTs, when comparing baseline scores to
any of the follow-up points. Immediately after the main
CBT phase, there was no difference between the CBT
group and usual care group for MLHFQ scores (SMD
−0.25, 95% CI −0.68 to 0.18, p = 0.26, I2 = 52%) (data
not shown). However, when all QoL data were combined,
there was a greater improvement in the CBT group than
the usual care group (SMD −0.31, 95% CI −0.58 to
−0.05, p = 0.02, I2 = 38%) (Fig. 4a), although there was
moderate heterogeneity (I2 values of 38 and 52%, respec-
tively). At 3 months, there were no differences in QoL
between the CBT and the usual care groups for either
MLHFQ scores (SMD −0.13, 95% CI −0.58 to 0.33,
p = 0.58, I2 = 0%) or across all QoL scales (SMD
−0.22, 95% CI −0.51 to 0.06, p = 0.12, I2 = 0%) (Fig.
4b). One study that compared CBT to exercise demon-
strated no difference in QoL between the groups at
3 months (MD −4.23, 95% CI −22.24 to 13.78).
Clinical outcomes
There were limited data on clinical outcomes, and hence, we
have limited power for comparison. Four studies provided
data on all-cause mortality [40, 42, Dekker 2010, Dekker
2011], with 8/69 (11.6%) deaths in CBT and 7/66 (10.6%)
deaths in usual care. There was no difference in all-cause
mortality and no evidence of heterogeneity (risk ratio 1.05,
95% CI 0.44 to 2.52, p = 0.63, I2 = 0%).
Hospitalisations were reported in four studies [40, 41,
Dekker 2010, Dekker 2011]. Overall, 55/129 (42.6%) and
55/128 (43.0%) patients in the CBT and usual care groups
were hospitalised, respectively, with no difference between
the two groups and no evidence of heterogeneity (risk ratio
0.99, 95% CI 0.75 to 1.32, p = 0.96, I2 = 0%).Ta
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Discussion
This systematic review and meta-analysis suggests that
CBT may be more effective than usual care at improving
depression in heart failure patients initially after the CBT
sessions. This difference was sustained 3 months after
completion of the CBT sessions; however, these were high-
ly selected patients in selected centres with varied compar-
ators and subjective outcome measures (depression and
QoL). The improvement in depression scores evident at
3 months was greater in two RCTs [41, 42]. This may be
due to the frequency and duration of the CBT, which were
weekly and over a period of time [41, 42], as opposed to a
single CBT session [40, Dekker 2010, Dekker 2011]. For
quality of life, CBT showed a greater improvement when
compared to usual care initially after the main CBT phase;
however, there was no evidence of a difference in QoL
between the two groups at subsequent time-points. There
was no evidence of CBT having an effect on either
hospitalisation or mortality.
This systematic review was conducted to evaluate the
effec t s of CBT on depress ion , qua l i ty of l i fe ,
hospitalisation and mortality in heart failure patients.
Previously, there have been two systematic reviews [3,
24] that evaluated the effects of psychological interven-
tions on depression in heart failure patients. However, the
first, a 2005 Cochrane review on psychological interven-
tions for depression in heart failure [3], found no relevant
RCTs, highlighting the need for RCTs on psychological
interventions to be conducted. The second, a 2012 sys-
tematic review on the effects of interventions on depres-
sion in heart failure, only identified one RCT with a CBT
intervention, concluding that there was insufficient evi-
dence on the effects of CBT [24]. Therefore, the emer-
gence of new RCTs, and the lack of conclusive evidence
from previous systematic reviews on this topic, justifies
the need for the current systematic review to evaluate the
effects of CBT in heart failure patients.
Despite the findings of this systematic review, there are
several limitations that need to be acknowledged. The
Quality of life inially aer main CBT phase (all quality of life scales)
Study Standardised
Mean Difference
95% Confidence
Interval
Gary 2010 -0.11 -0.83, 0.61
Dekker 2010 0.07 -1.03, 1.16
Dekker 2011 0.99 -0.37, 2.34
Dekker 2012 -0.83 -1.52, -0.13
Freedland 2015 -0.36 -0.70, -0.01
Overall effect (p=0.02)
Heterogeneity (I2=38%, p=0.17)
-0.31 -0.58, -0.05
Quality of life 3 months aer main CBT phase (all quality of life scales)
Study Standardised
Mean Difference
95%Confidence
Interval
Gary 2010 -0.14 -0.58, 0.86
Dekker 2010 0.11 -1.25, 1.46
Dekker 2011 0.24 -1.47, 1.96
Dekker 2012 -0.52 -1.22, 0.19
Freedland 2015 -0.28 -0.65, -0.08
Overall effect (p=0.12)
Heterogeneity (I2=0%, p=0.69)
-0.22 -0.51, 0.06
b
a
Fig. 4 Forest plots summarising the effectiveness of CBT versus usual care on quality of life. Meta-analysis of all quality of life scales (MLHFQ and
KCCQ) at the first time-point initially after the main CBT phase (a) and at 3 months (b). CBT cognitive behavioural therapy
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searches identified only five RCTs, which demonstrate the
lack of experimental studies assessing the effects of CBT
in heart failure patients. Two of the RCTs had small sam-
ple sizes (≤30), which were particularly problematic with
longer follow-up due to attrition. There was also a lack of
studies that evaluated the effects of CBT with follow-up
≥6 months, which would have been useful in assessing the
long-term sustainability of the effects of CBT. Overall, the
methodological quality of studies was unclear due to in-
sufficient information provided. For two studies, only the
original data and study protocols could be accessed
[Dekker 2010; Dekker 2011], which led to a lack of clar-
ity over certain risks of biases. There was performance
bias in the RCTs due to a lack of blinding of participants,
but this was unavoidable due to the nature of CBT inter-
ventions. Two outcome measures (depression and QoL)
were subjective and assessed by self-reported question-
naires, which may have introduced social desirability bias.
Data on hospitalisations and deaths were limited and were
not reported in all studies. There was also insufficient data
to determine the relative effects of CBT in comparison to
exercise for depression in heart failure patients, as there
was only one RCT that utilised exercise as a comparator.
One advantage of this review, however, was that addition-
al data was obtained by contacting lead authors to better
inform the systematic review and enable the meta-analy-
sis. Future RCTs on the effects of CBT for heart failure
patients would benefit from recruiting larger numbers of
participants, delivering weekly CBT sessions over a lon-
ger period of time, with long-term follow-up (≥6 months),
and reporting on outcomes such as hospitalisations or
mortality.
Current NICE guidelines on chronic heart failure [45] state
that depression should be treated in accordance with the
guidelines for adults with depression [22] and those for adults
with a chronic physical health problem [46]; however, the
evidence used to evaluate the effects of CBT on depression
are not specific to heart failure patients. This may be due to the
lack of randomised controlled trials on CBT for depression in
heart failure prior to the publication of these guidelines. The
2016 Scottish Intercollegiate Guidelines Network (SIGN)
guidelines on the management of chronic heart failure offer
a conditional recommendation that CBTshould be considered
in heart failure patients with depression [47]. The evidence for
this recommendation is based on a single RCT on CBT and a
systematic review on interventions [24] that included only a
single CBT intervention study. Therefore, the current system-
atic review and meta-analysis extends previous work and pro-
vides a comprehensive review of available evidence for the
effects of CBT for depression in heart failure patients. The
findings from this research have identified an area of further
study in heart failure and demonstrated the potential of CBT in
selected research centres.
Conclusion
CBT may be more effective than usual care at improving de-
pression in heart failure patients initially after the main CBT
phase and 3 months afterwards. CBT also appears to be more
effective than usual care at improving quality of life in heart
failure patients initially after the main CBT phase, but this effect
was not sustained 3 months later. There were no observable
differences between CBT and usual care for hospitalisations or
mortality. However, these findings were limited by the small
sample sizes in some studies, lack of long-term follow-up, use
of subjective outcome measures and insufficient information to
assess methodological quality. Larger andmore robust RCTs are
needed to ascertain the long-term benefits and cost-effectiveness
of a CBT intervention for depression in heart failure patients.
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